Keeping Up With Mood Disorder Research at APA

Gus Alva, MD, discussed the importance of continuing medical education, advances in depression treatment, and the clinical imperative of ruling out bipolar disorder before initiating antidepressant therapy.

Alva argued that conference attendance is essential to lifelong learning in psychiatry, characterizing regional meetings as efficient venues for acquiring "contemporary and applicable knowledge" in a condensed format. He described combating stigma as among the most impactful contributions psychiatrists can make, noting that patients who do not recognize depression as a medical condition requiring intervention may fail to perceive that recovery is possible.

On pharmacotherapy, Alva emphasized the field's evolution beyond monoaminergic mechanisms, citing glutamatergic and GABAergic agents, selective receptor-targeted approaches, augmentation strategies, and neuromodulation as expanding the treatment armamentarium for depression. He framed this as complementing rather than replacing established therapies, while underscoring the clinical value of having additional tools available.

Alva identified the differential diagnosis of unipolar depression versus a depressive episode in bipolar disorder as the most consequential diagnostic decision in this space, noting that the 2 presentations may be phenomenologically indistinguishable at the depressive pole.¹ He cautioned that initiating antidepressant monotherapy without a mood stabilizer in a patient with unrecognized bipolar disorder risked worsening the clinical course, emphasizing that "above all we don't want to harm the patient."²

Dr Alva is a board-certified psychiatrist and the Mood Disorders Section Editor for Psychiatric Times.

References

1. Cuellar AK, Johnson SL, Winters R. Distinctions between bipolar and unipolar depression. Clin Psychol Rev. 2005;25(3):307-39.

2. Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6(1):25.